

Published in final edited form as:

*Org Biomol Chem.* 2014 August 28; 12(32): 6190–6199. doi:10.1039/c4ob01088d.

## Synthetic and Mechanistic Aspects of the Regioselective Base-Mediated Reaction of Perfluoroalkyl- and Perfluoroarylsilanes with Heterocyclic *N*-Oxides

David E. Stephens, Gabriel Chavez, Martin Valdes, Monica Dovalina, Hadi D. Arman, and Oleg V. Larionov

Department of Chemistry, University of Texas at San Antonio, San Antonio, Texas, United States of America. Fax: +1 210 458 7428; Tel: +1 210 458 6050

Oleg V. Larionov: oleg.larionov@utsa.edu

### Abstract

The scope and mechanistic implications of the direct transformation of heterocyclic *N*-oxides to 2-trifluoromethyl-, and related perfluoroalkyl- and perfluoroaryl-substituted *N*-heterocycles has been studied. The reaction is effected by perfluoroalkyl- and perfluorophenyltrimethylsilane in the presence of strong base. In situ displacement of the *para*-fluoro substituent in the pentafluorophenyl ring and the methoxy group in 8-methoxyquinolines with additional nucleophiles allows for further site-selective refunctionalization of the *N*-heterocyclic products.

### Introduction

Aromatic compounds bearing fluorine-containing alkyl and aryl substituents are important structural motifs of numerous bioactive compounds<sup>1</sup> and advanced functional materials.<sup>2</sup> Due to the unique electronic properties of fluorine, introduction of fluorinated alkyl groups can significantly improve metabolic stability, lipophilicity and binding properties of small organic molecules. As a consequence of the central position of *N*-heterocycles in medicinal and agricultural chemistry, introduction of trifluoromethyl and related groups into the *N*-heteroarene core has been successfully employed for the development of a number of drugs and agrochemicals (Figure 1). Hence, regioselective trifluoromethylation reactions of *N*-heterocycles have recently attracted significant attention.<sup>3</sup> In particular, introduction of trifluoromethyl and difluoromethyl substituents in the C2-position of pyridines, quinolines and related six-membered nitrogenous aromatic heterocycles is a potentially useful synthetic strategy that continues to pose a significant methodological challenge.<sup>4</sup>

Heterocyclic *N*-oxides are important and readily available<sup>5</sup> synthetic intermediates that have recently been used as substrates for the regioselective transition metal-catalyzed preparation of various *N*-heterocycles bearing aryl-, alkyl- and heteroatom-substituents in the C2

position.<sup>6</sup> In addition, a number of non-catalytic transformations, such as halogenations<sup>7</sup> and aminations,<sup>8</sup> have also been developed.

Trimethyl(trifluoromethyl)silane (**1**) and related perfluoroalkyl/arylsilanes are among the most cost-effective sources of the corresponding fluorinated alkyl and aryl groups for organic synthesis.<sup>9</sup> However their application is sometimes hindered by the unproductive  $\alpha$ -elimination of the fluoride and other side processes, and a careful selection of reaction conditions is required to achieve high yields.<sup>10</sup>

We herein report a study of the reaction of heterocyclic *N*-oxides with fluorinated alkylsilanes and trimethyl(pentafluorophenyl)-silane that directly affords 2-trifluoromethyl- and related substituted *N*-heterocycles regioselectively and in good to excellent yields. A survey of the patent literature shows that, although a reaction of **1** with two substituted quinoline *N*-oxides was used to access the corresponding 2-trifluoromethylquinolines,<sup>11</sup> the scope and utility of this transformation were not systematically explored, and potential use of other perfluoroalkylsilanes was not investigated, which prevented its wider application in the mainstream synthetic organic, medicinal and materials chemistry. Recently, Kuninobu, Kanai and co-workers conducted an elegant study on the reaction of **1** with heterocyclic *N*-oxides that is mediated by a combination of cesium fluoride and (trifluoromethyl)difluoroboron as a Lewis acidic *N*-oxide activator.<sup>12</sup> However, this method is limited to trifluoromethylation, and, in addition, the (trifluoromethyl)difluoroboron has to be generated from expensive potassium (trifluoromethyl)trifluoroborate. Another interesting approach to C2-trifluoromethylation of azines was described by Makosza and co-workers.<sup>13</sup> In this case azines were first transformed into the corresponding *N*-(*p*-methoxybenzyl)azinium salts that were reacted with silane **1** in the presence of potassium fluoride. Treatment of the addition products with cerium ammonium nitrate led to removal of the PMB group and oxidative aromatization to give 2-trifluoromethylated azines.

We also describe several unexpected concomitant dual substitution processes that can be used to increase structural diversity of the *N*-heterocyclic motifs. In particular, a facile substitution of 8-methoxy group in the quinoline core by *tert*-butoxide represents an unusual example of aromatic nucleophilic substitution.

## Results and Discussion

We began our study by examining the reaction between quinoline *N*-oxide (**2**) and silane **1** (Table 1) in the presence of several fluoride salts and bases. While formation of product **3** (11%) was observed upon reacting **1** and **2** in the presence of 0.2 equiv of TBAF in THF, the reaction was accompanied by formation of quinoline in comparable amounts. The yield of **3** was improved in toluene/THF (1:1), albeit with concomitant increase in formation of quinoline (entry 2).

No improvement was observed at elevated temperatures (e.g. entry 3). Further increase in yields of **3** was achieved with TASF [tris(dimethylamino)sulfonium difluorotrimethylsilicate] and cesium fluoride as fluoride sources. Both salts also gave higher **3**/quinoline. Attempts to catalyze the reaction by transition metal salts (e.g. copper(I)

triflate) or increase the electrophilicity of the *N*-oxide via coordination to a Lewis acid (e.g. MgCl<sub>2</sub>) proved unsuccessful (entries 6 and 7). On the other hand, use of potassium *tert*-butoxide (1.1 equiv) led to faster conversion, however with concomitant acceleration of the formation of quinoline. Further optimization was achieved by increasing the amount of the base and lowering the temperature to -20 °C. This way the formation of quinoline was effectively minimized, and a clean conversion to product **3** took place.

After completion of the optimization study we set out to explore the scope of the novel trifluoromethylation method with other heterocyclic *N*-oxides (Table 2).

The reaction generally exhibits a broad scope of applicable substrates. Thus, silane **1** reacted readily with substituted quinoline, pyridine, phenanthridine and isoquinoline *N*-oxides giving rise to the corresponding products in a highly regioselective fashion. In none of the cases were any other regioisomers observed or isolated. Halogenated substrates are well tolerated. *N*-Oxides that have a labile 4-thio and 4-oxy substituents that are known to be prone to facile nucleophilic displacement of the C4-group,<sup>14</sup> afford the desired 2-trifluoromethylquinolines in good yields. In general, bi- and tricyclic *N*-heterocyclic *N*-oxides reacted more readily and gave the products in higher yields, while 4-phenylpyridine *N*-oxide was less reactive and afforded the trifluoromethylated product **10** in a 28% yield. The reaction is best carried out at -20 °C for all substrates.

We have also studied the performance of other fluorinated alkylsilanes in the base-mediated reaction with *N*-oxides (Table 3). In general, both (pentafluoroethyl)- and (heptafluoropropyl)-trimethylsilane proved to be very efficient perfluoroalkylating reagents. The products were obtained in good to excellent yields under the optimized conditions at -20 °C. (Difluoromethyl)trimethylsilane, on the other hand, was less efficient, with somewhat lower yields of the products and higher loadings of the silane and potassium *tert*-butoxide. Trimethyl(pentafluorophenyl)-silane afforded the desired product **17** with one equivalent of potassium *tert*-butoxide in 17% yield. When the previously optimized amount of the base (3 equiv) was used an unexpected displacement of the fluoride in the para-position with respect to the *N*-heterocyclic residue by *tert*-butoxide took place (Table 4). The reaction also worked well with sodium thiophenolate and sodium ethanethiolate as nucleophiles. This reactivity is in line with previously reported observations of facile and regioselective nucleophilic para-substitution of the fluoride in other pentafluoroarenes.<sup>15</sup>

Another unusual substitution reaction was observed with 5,7-dichloro-8-methoxyquinoline *N*-oxide (**27**). In this case, a facile substitution of the 8-methoxy group by the *tert*-butoxide took place with concomitant perfluoroalkylation (Scheme 1).

Substitution of the 8-methoxy group in the 8-alkoxyquinoline series has previously been achieved only at elevated temperatures,<sup>16</sup> and in the presence of a transition-metal catalyst.<sup>17</sup>

It is possible that introduction of the electron-withdrawing 2-perfluoroalkyl group in the quinoline facilitates the nucleophilic aromatic substitution. The reaction takes place after installation of the perfluoroalkyl group, since no 8-methoxy group displacement as observed

when *N*-oxide **27** was treated with potassium *tert*-butoxide in the absence of **1** under the standard reaction conditions.

The reaction was exploited for the synthesis of new analogues of antimicrobial drug chlorquinaldol (**30**). The *tert*-butyl group removal with triflic acid afforded chlorquinaldol derivatives **31** and **32** in 88 and 90% yields.

Based on the previous studies<sup>18,10b</sup> it is plausible that *tert*-butoxide activates silane **1** by forming a pentacoordinated silicon nucleophile that subsequently binds to the oxygen atom of the *N*-oxide. The rate-limiting transfer of the trifluoromethyl group to C2 is then followed by fast deprotonation and elimination of the trimethylsiloxide. This rationale is supported by a relatively small kinetic isotope effect ( $k_H/k_D = 1.2$ ) in the reaction of isoquinoline *N*-oxide (**33**) with **1** (Scheme 2).

## Conclusions

In conclusion, we have investigated the scope and synthetic utility of a reaction of heterocyclic *N*-oxides and perfluoroalkylsilanes that affords 2-perfluoroalkyl/aryl-substituted nitrogenous heterocycles in good to excellent yields. Potassium *tert*-butoxide has been identified as the base of choice for the nucleophilic activation of the silane. The reported transformation of heterocyclic *N*-oxides to 2-trifluoromethyl *N*-heterocycles and related compounds can be used to access fluorinated heterocyclic scaffolds of practical synthetic and medicinal value, as demonstrated by the synthesis of two new fluorine-containing analogues of the antimicrobial drug chlorquinaldol. In addition, small kinetic isotope effect points toward the addition of the trifluoromethyl anion as the rate-determining step that is followed by fast elimination.

## Experimental section

### General methods

Tetrahydrofuran was distilled from sodium benzophenone ketyl. Isoquinoline-*N*-oxide was purchased from Alfa Aesar, 4-phenylpyridine *N*-oxide, (pentafluorophenyl)trimethylsilane, and (pentafluoroethyl)trimethylsilane were purchased from TCI. (Trifluoromethyl)trimethylsilane was purchased from Matrix Scientific, and (difluoromethyl)trimethylsilane was purchased from Oakwood Chemicals. All other chemicals were used as commercially available (Sigma-Aldrich, Acros, Alfa Aesar, Combi-Blocks, Strem). All reactions were conducted with continuous magnetic stirring under an atmosphere of argon in oven-dried glassware. Low-temperature experiments were conducted using a Neslab Cryotrol CB-80 cryostat. Reactions were monitored by TLC until deemed complete using silica gel-coated glass plates (Merck Kieselgel 60 F254). Plates were visualized under ultraviolet light (254 nm). Column chromatography was performed using CombiFlash Rf-200 (Teledyne-Isco) automated flash chromatography system with RediSep columns. <sup>1</sup>H, <sup>13</sup>C and <sup>19</sup>F NMR spectra were recorded at 300 and 500 (<sup>1</sup>H), and 75.5, 125 MHz, and 282 MHz (<sup>19</sup>F) on Varian Mercury VX 300 and Agilent Inova 500 instruments in CDCl<sub>3</sub> solutions if not otherwise specified. Chemical shifts ( $\delta$ ) are reported in parts per million (ppm) from the residual solvent peak and coupling constants ( $J$ ) in Hz. Infrared

measurements were carried out neat on a Bruker Vector 22 FT-IR spectrometer fitted with a Specac diamond attenuated total reflectance (ATR) module.

### General procedure (GP1) for the reaction of heterocyclic *N*-oxides with perfluoroalkyl- and pentafluorophenylsilanes

To a stirred solution of heterocyclic *N*-oxide (0.2 mmol), 3 Å molecular sieves (25 mg), and trimethyl(trifluoromethyl)silane (45 µL, 0.3 mmol, 1.5 equiv.) in tetrahydrofuran (1 mL) at -20 °C was added potassium *tert*-butoxide (66 mg, 0.6 mmol, 3 equiv.) in 1 equiv. portions every 10 min. The reaction was allowed to stir an additional 10 min before being diluted with a saturated aqueous solution of ammonium chloride (2 mL) and the aqueous layer extracted with dichloromethane (3 × 5 mL). The combined organic layers were dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by column chromatography [hexanes/EtOAc/silica gel] to yield the desired product.

### Experimental procedures and spectroscopic data

**2-(Trifluoromethyl)quinoline<sup>13</sup> (3)**—According to GP1, **2** (50 mg, 0.34 mmol), 3 Å molecular sieves (50 mg), and trimethyl(trifluoromethyl)silane (76 µL, 0.51 mmol, 1.5 equiv.) in tetrahydrofuran (1.8 mL) at -20 °C was added potassium *tert*-butoxide (116 mg, 1.03 mmol, 3 equiv.) in 3 portions over 30 min. After 10 min the reaction was worked up and the crude product purified by column chromatography to yield 2-(trifluoromethyl)quinoline (**3**) (59 mg, 87%). – <sup>1</sup>H NMR (500 MHz): 7.69 (1 H, td, *J* = 1, 7 Hz), 7.75 (1 H, d, *J* = 8.5 Hz), 7.84 (1 H, td, *J* = 1.5, 7 Hz), 7.92 (1 H, dd, *J* = 1.5, 8.5 Hz), 8.25 (1 H, dd, *J* = 1, 8.5 Hz), 8.37 (1 H, d, *J* = 8.5 Hz) ppm. – <sup>13</sup>C NMR (125 MHz): 116.7, 116.8, 127.7, 128.6, 130.1, 130.8, 138.1, 147.2 ppm. – <sup>19</sup>F NMR (282 MHz): -67.4 ppm. – IR: 910, 1087, 1128, 1214, 1274, 1303, 1431, 2930, 3063 cm<sup>-1</sup>.

**6-(Trifluoromethyl)phenanthridine<sup>14</sup> (4)**—According to GP1, phenanthridine *N*-oxide (39 mg, 0.20 mmol), 3 Å molecular sieves (25 mg), and trimethyl(trifluoromethyl)silane (40 µL, 0.22 mmol, 1.1 equiv.) at -20 °C was reacted with potassium *tert*-butoxide (66 mg, 0.60 mmol, 3 equiv.) in 3 portions over 30 min. The reaction was allowed to stir an additional 10 min before being worked up and purified by column chromatography to yield phenanthridine **4** (41 mg, 82 %). – <sup>1</sup>H NMR (500 MHz): 7.79 – 7.85 (3 H, m), 7.96 (1 H, dt, *J* = 1.5 Hz, 8.5 Hz), 8.32 (1 H, dd, *J* = 1.5, 7 Hz), 8.41 (1 H, dd, *J* = 0.5, 8.5 Hz), 8.65 (1 H, dd, *J* = 1, 7 Hz), 8.74 (1 H, d, *J* = 8.5 Hz) ppm. – <sup>13</sup>C NMR (75 MHz): 120.1, 121.8, 122.1, 122.6, 125.1, 125.9, 125.9, 126.0, 128.1, 128.3, 129.2, 129.4, 131.1, 131.4, 134.0, 141.7 ppm. – <sup>19</sup>F NMR (282 MHz): -63.5 ppm. – IR: 1179, 1395, 1418, 1506, 2988, 3026 cm<sup>-1</sup>.

**8-Methoxy-2-(trifluoromethyl)quinoline<sup>15</sup> (5)**—According to GP1, to a stirred solution of 8-methoxyquinoline *N*-oxide (35 mg, 0.20 mmol) and trimethyl(trifluoromethyl)silane (45 µL, 0.30 mmol, 1.50 equiv.) in tetrahydrofuran (1 mL) was added potassium *tert*-butoxide (66 mg, 0.60 mmol, 3 equiv.) in 3 portions over 30 min. After 10 min the reaction was worked up and the crude product purified by column chromatography to yield quinoline **5** (45 mg, 98%). – <sup>1</sup>H NMR (500 MHz): 4.12 (3 H, s), 7.15 (1 H, d, *J* = 7.5 Hz), 7.48 (1 H, d, *J* = 8 Hz), 7.61 (1 H, t, *J* = 8 Hz), 7.77 (1 H, d, *J* = 8.5 Hz), 8.34 (1 H, d, *J* = 8.5 Hz) ppm. – <sup>13</sup>C NMR (125 MHz): 56.4, 109.2, 118.5, 119.2,

129.1, 130.0, 137.7, 139.5, 145.8, 136.2 (d), 156.0 ppm. –  $^{19}\text{F}$  NMR (282 MHz): –67.0 ppm. – IR: 1067, 1110, 1213, 1259, 1329, 1432, 1445, 1561, 2937, 3046  $\text{cm}^{-1}$ .

**7-Chloro-4-methoxy-2-(trifluoromethyl)quinoline (6)**—According to GP1, to a stirred solution of 7-chloro-4-methoxyquinoline *N*-oxide (42 mg, 0.20 mmol) and trimethyl(trifluoromethyl)silane (45  $\mu\text{L}$ , 0.30 mmol, 1.5 equiv.) in tetrahydrofuran (1 mL) was added potassium *tert*-butoxide (66 mg, 0.60 mmol, 3 equiv.) in 3 portions over 30 min. After 10 min the reaction was worked up and the crude product purified by column chromatography to yield quinoline **6** (23 mg, 43 %). –  $^1\text{H}$  NMR (500 MHz): 4.14 (3 H, s), 7.05 (1 H, s), 7.57 (1 H, dd,  $J = 1, 8$  Hz), 8.14–8.20 (2 H, m) ppm. –  $^{13}\text{C}$  NMR (125 MHz): 56.3, 96.4, 120.1, 120.2, 122.4, 123.4, 128.5, 137.1, 148.6, 150.1, 150.4, 163.9 ppm. –  $^{19}\text{F}$  NMR (282 MHz): –68.0 ppm. – IR: 1110, 1215, 1325, 1448, 2988, 2999, 3026  $\text{cm}^{-1}$ . – MS (ESI): 261.0 [M], HRMS: 262.0449, calcd: 262.0241 [M+H $^+$ ].

**5-Bromo-2-(trifluoromethyl)quinoline<sup>16</sup> (7)**—According to GP1, 5-bromoquinoline *N*-oxide (111 mg, 0.50 mmol), 3Å molecular sieves (100 mg), and trimethyl(trifluoromethyl)silane (115  $\mu\text{L}$ , 0.75 mmol, 1.5 equiv.) at –20 °C were reacted with potassium *tert*-butoxide (56 mg, 1.50 mmol, 3 equiv.) in 3 portions over 30 min. After 10 min the reaction was worked up and the crude product purified by column chromatography to yield quinoline **7** (123 mg, 94 %). –  $^1\text{H}$  NMR (300 MHz): 7.68 (1 H, dt,  $J = 2, 8$  Hz), 7.83 (1 H, dd,  $J = 2, 9.5$  Hz), 7.95 (1 H, d,  $J = 8$  Hz), 8.20 (1 H, d,  $J = 8$  Hz), 8.75 (1 H, dd,  $J = 2, 9.5$  Hz) ppm. –  $^{13}\text{C}$  NMR (125 MHz): 117.9, 120.2, 121.8, 122.4, 124.6, 130.0, 132.2, 137.9, 147.9, 148.5 (quart.,  $J = 2.5$  Hz) ppm. –  $^{19}\text{F}$  NMR (282 MHz): –67.6 ppm. – IR: 1102, 1207, 1321, 1357, 1434, 1514, 2931, 2970, 3025  $\text{cm}^{-1}$ .

**1-(Trifluoromethyl)isoquinoline<sup>17</sup> (8)**—According to GP1, isoquinoline-*N*-oxide (207 mg, 1.42 mmol), 3Å molecular sieves (100 mg), and trimethyl(trifluoromethyl)silane (315  $\mu\text{L}$ , 2.13 mmol, 1.5 equiv.) at –20 °C were reacted with potassium *tert*-butoxide (477 mg, 4.26 mmol, 3 equiv.) in 3 portions over 30 min. After 10 min the reaction worked up and the crude product purified by column chromatography to yield isoquinoline **8** (259 mg, 92 %). –  $^1\text{H}$  NMR (500 MHz): 7.71 (1 H, dt,  $J = 2, 8.5$  Hz), 7.78 (1 H, t,  $J = 8$  Hz), 7.84 (1 H, d,  $J = 5.5$  Hz), 7.92 (1 H, d,  $J = 8$  Hz), 8.30 (1 H, d,  $J = 8.5$  Hz), 8.59 (1 H, d,  $J = 5.5$  Hz) ppm. –  $^{13}\text{C}$  NMR (125 MHz): 124.6 (m), 127.5, 128.8, 130.9, 137.1, 140.7, 146.3 (quart.,  $J = 33$  Hz) ppm. –  $^{19}\text{F}$  NMR (282 MHz): –63.0 ppm. – IR: 1024, 1141, 1192, 1233, 1303, 1363, 1400, 1507, 2879, 2974, 3021  $\text{cm}^{-1}$ .

**7-Chloro-4-phenyl-2-(trifluoromethyl)quinoline<sup>18</sup> (9)**—According to GP1, to a stirred solution of 7-chloro-4-phenylquinoline *N*-oxide (51 mg, 0.20 mmol) and trimethyl(trifluoromethyl)silane (45  $\mu\text{L}$ , 0.30 mmol, 1.5 equiv.) in tetrahydrofuran (1 mL) was added potassium *tert*-butoxide (66 mg, 0.60 mmol, 3 equiv.) in 3 portions over 30 min. After 10 min the reaction was worked up and the crude product purified by column chromatography to yield quinoline **9** (46 mg, 75 %). –  $^1\text{H}$  NMR (300 MHz): 7.24 (1 H, d,  $J = 4$  Hz), 7.45–7.56 (5 H, m), 7.88 (1 H, d,  $J = 5.5$  Hz), 8.55 (1 H, d,  $J = 4$  Hz), 8.85 (1 H, d,  $J = 1.5$  Hz) ppm. –  $^{13}\text{C}$  NMR (125 MHz): 117.2, 120.3, 122.5, 125.9, 127.3, 128.3, 128.9,



1293, 129.3, 129.4, 129.6, 136.7 (d,  $J = 1$  Hz), 148.2, 148.7 (m), 151.1 ppm. –  $^{19}\text{F}$  NMR (282 MHz): –67.7 ppm. – IR: 1099, 1167, 1266, 1384, 1448, 1502, 2878, 2938, 3041  $\text{cm}^{-1}$ .

**4-Phenyl-2-(trifluoromethyl)pyridine<sup>19</sup> (10)**—According to GP1, 4-phenylpyridine *N*-oxide (35 mg, 0.20 mmol), 3 Å molecular sieves (25 mg), and trimethyl(trifluoromethyl)silane (45  $\mu\text{L}$ , 0.30 mmol, 1.5 equiv.) at –20 °C were reacted with potassium *tert* butoxide (66 mg, 0.60 mmol, 3 equiv.) in 3 portions over 10 min. After 10 min the reaction was worked up and the crude product purified by column chromatography to yield pyridine **10** (12 mg, 28 %). –  $^1\text{H}$  NMR (300 MHz): 7.45 – 7.57 (3 H, m), 7.63–7.71 (3 H, m), 7.90 (1 H, s), 8.78 (1 H, d,  $J = 5$  Hz) ppm. –  $^{13}\text{C}$  NMR (75 MHz): 118.1 (m), 120.6 (m), 121.7, 123.8, 126.7, 123.8, 126.7, 129.0, 129.5, 136.5, 150.1 ppm. –  $^{19}\text{F}$  NMR (282 MHz): –68.0 ppm. – IR: 1023, 1149, 1184, 1261, 1336, 1460, 2854, 2926, 3026  $\text{cm}^{-1}$ .

**5-Chloro-8-methoxy-2-(trifluoromethyl)quinoline (11)**—According to GP1, to a stirred solution of 5-chloro-8-methoxyquinoline *N*-oxide (42 mg, 0.20 mmol) and trimethyl(trifluoromethyl)silane (45  $\mu\text{L}$ , 0.30 mmol, 1.5 equiv.) in tetrahydrofuran (1 mL) was added potassium *tert*-butoxide (66 mg, 0.60 mmol, 3 equiv.) in 3 portions over 30 min. After 10 min the reaction was worked up and the crude product purified by column chromatography to yield quinoline **11** (48 mg, 92 %). –  $^1\text{H}$  NMR (500 MHz): 4.11 (3 H, s), 7.08 (1 H, dd,  $J = 2.5, 8.5$  Hz), 7.68 (1 H, dd,  $J = 2, 8.5$  Hz), 7.89 (1 H, dd,  $J = 2.5, 8.5$  Hz), 8.75 (1 H, dd,  $J = 2, 8.5$  Hz) ppm. –  $^{13}\text{C}$  NMR (125 MHz): 56.5, 108.8, 110.0, 118.3, 120.3, 122.5, 127.8, 128.6, 135.4, 139.7, 144.3 (d,  $J = 2$  Hz), 155.1 ppm. –  $^{19}\text{F}$  NMR (282 MHz): –67.1 ppm. – IR: 1106, 1186, 1213, 1310, 1372, 1463, 1509, 2842, 2936, 3003  $\text{cm}^{-1}$ . – MS (ESI): 262.0, HRMS: 262.0300, calcd: 262.0241 [ $\text{M}+\text{H}^+$ ].

**7-Chloro-4-(isopropylthio)-2-(trifluoromethyl)quinoline (12)**—According to GP1, to a stirred solution of 7-chloro-4-(isopropylthio)quinoline *N*-oxide (51 mg, 0.20 mmol) and trimethyl(trifluoromethyl)silane (45  $\mu\text{L}$ , 0.30 mmol, 1.5 equiv.) in tetrahydrofuran (1 mL) was added potassium *tert*-butoxide (66 mg, 0.6 mmol, 3 equiv.) in 3 portions over 30 min. After 10 min the reaction was worked up and the crude product purified by column chromatography to yield quinoline **12** (61 mg, 63 %). –  $^1\text{H}$  NMR (500 MHz): 1.52 (6 H, d,  $J = 7$  Hz), 3.79 (1 H, sept.,  $J = 7$  Hz), 7.51 (1 H, s), 7.60 (1 H, dd,  $J = 2, 9$  Hz), 8.14 (1 H, d,  $J = 9$  Hz), 8.18 (1 H, d,  $J = 2$  Hz) ppm. –  $^{13}\text{C}$  NMR (125 MHz): 22.6, 36.1, 112.4, 120.3, 122.4, 125.0, 125.7, 129.0, 129.5, 137.0, 147.0, 138.0 (d), 150.8 ppm. –  $^{19}\text{F}$  NMR (282 MHz): –67.9 ppm. – IR: 1027, 1105, 1197, 1238, 1340, 1560, 2956, 3010, 3345  $\text{cm}^{-1}$ . – MS (ESI): 305.8, HRMS: 306.2045, calcd: 306.0326 [ $\text{M}+\text{H}^+$ ].

**4-(*tert*-Butylthio)-7-chloro-2-(trifluoromethyl)quinoline (13)**—According to GP1, to a stirred solution of 4-(*tert*-butylthio)-7-chloroquinoline *N*-oxide (64 mg, 0.20 mmol) and trimethyl(trifluoromethyl)silane (45  $\mu\text{L}$ , 0.30 mmol, 1.5 equiv.) in tetrahydrofuran (1 mL) was added potassium *tert*-butoxide (66 mg, 0.60 mmol, 3 equiv.) in 3 portions over 30 min. After 10 min the reaction was worked up and the crude product purified by column chromatography to yield quinoline **13** (42 mg, 66 %). –  $^1\text{H}$  NMR (500 MHz): 1.70 (9 H, s), 7.64 (1 H, dd,  $J = 2, 9$  Hz), 7.91 (1 H, s), 8.23 (1 H, dd,  $J = 2$  Hz), 8.56 (1 H, d,  $J = 9$  Hz) ppm. –  $^{13}\text{C}$  NMR (75 MHz): 31.3, 49.5, 119.4, 123.2, 127.6, 129.3, 129.8, 129.9, 137.1,

146.4, 147.7 (m) ppm. – IR: 1144, 1213, 1345, 2899, 2987, 3033  $\text{cm}^{-1}$ . – MS (ESI): 319.8, HRMS: 319.3671, calcd: 320.0482  $[\text{M}+\text{H}^+]$ .

**7-Chloro-4-(isopropylthio)-2-(perfluoropropyl)quinoline (14)**—According to GP1, to a stirred solution of 7-chloro-4-(isopropylthio)quinoline *N*-oxide (51 mg, 0.20 mmol), 3 Å molecular sieves (50 mg), and trimethyl(heptafluoropropyl)silane (61  $\mu\text{L}$ , 0.30 mmol, 1.5 equiv.) in tetrahydrofuran (1 mL) was added potassium *tert*-butoxide (67 mg, 0.60 mmol, 3 equiv.) in 3 portions over 30 min at  $-20\text{ }^\circ\text{C}$ . After 10 min the reaction was worked up and the crude product purified by column chromatography to yield quinoline **14** (63 mg, 78 %). –  $^1\text{H}$  NMR (500 MHz): 7.49 (1 H, s), 7.61 (1 H, dd,  $J = 2, 9$  Hz), 8.14 (1 H, d,  $J = 9$  Hz), 8.20 (1 H, d,  $J = 2$  Hz) ppm. –  $^{13}\text{C}$  NMR (125 MHz): 22.4, 36.1, 113.9, 125.0, 125.6, 128.3, 129.2, 129.7, 137.0, 147.1, 147.5, 150.4 ppm. –  $^{19}\text{F}$  NMR (282 MHz):  $-80.1, -114.9, -126.1$  ppm. – IR: 1076, 1153, 1231, 1304, 1371, 1431, 1567, 2928, 2970, 3035  $\text{cm}^{-1}$ .

**4-(tert-Butylthio)-7-chloro-2-(perfluoropropyl)quinoline (15)**—According to GP1, to a solution of 4-(*tert*-butylthio)-7-chloroquinoline *N*-oxide (54 mg, 0.20 mmol), 3 Å molecular sieves (50 mg), and trimethyl(heptafluoropropyl)silane (61  $\mu\text{L}$ , 0.30 mmol, 1.5 equiv.) in tetrahydrofuran (1 mL) was added potassium *tert*-butoxide (67 mg, 0.60 mmol, 3 equiv.) in 3 portions over 30 min at  $-20\text{ }^\circ\text{C}$ . After 10 min the reaction was worked up and the crude product purified by column chromatography to yield quinoline **15** (75 mg, 90 %). –  $^1\text{H}$  NMR (500 MHz): 1.42 (9 H, s), 7.65 (1 H, dd,  $J = 2, 9$  Hz), 7.91 (1 H, s), 8.26 (1 H, d,  $J = 2$  Hz), 8.58 (1 H, d,  $J = 9$  Hz) ppm. –  $^{13}\text{C}$  NMR (125 MHz): 31.3, 49.5, 109.2 (m), 112.6 (m), 116.0 (m), 119.7 (m), 124.8, 127.6, 128.3, 129.5, 129.8, 129.9, 137.1, 146.0, 147.4 (m), 147.9 ppm. –  $^{19}\text{F}$  NMR (282 MHz):  $-80.1, -114.9, -126.2$  ppm. – IR: 1063, 1122, 1191, 1231, 1305, 1408, 1558, 2901, 2970, 3060  $\text{cm}^{-1}$ . – MS (ESI): 457.9, HRMS: 457.9973, calcd: 457.9977  $[\text{M}+\text{K}^+]$ .

**5-Bromo-2-(perfluoroethyl)quinoline (16)**—According to GP1, to a stirred solution of 5-bromoquinoline *N*-oxide (45 mg, 0.20 mmol), 3 Å molecular sieves (50 mg), and trimethyl(pentafluoroethyl)silane (53  $\mu\text{L}$ , 0.30 mmol, 1.5 equiv.) in tetrahydrofuran (1 mL) was added potassium *tert*-butoxide (67 mg, 0.60 mmol, 3 equiv.) in 3 portions over 30 min at  $-20\text{ }^\circ\text{C}$ . After 10 min the reaction was worked up and the crude product purified by column chromatography to yield quinoline **16** (54 mg, 84 %). –  $^1\text{H}$  NMR (500 MHz): 7.69 (1 H, t,  $J = 7.5$  Hz), 7.86 (1 H, d,  $J = 8.5$  Hz), 7.97 (1 H, d,  $J = 7.5$  Hz), 8.23 (1 H, d,  $J = 8.5$  Hz), 8.76 (1 H, d,  $J = 8.5$  Hz) ppm. –  $^{13}\text{C}$  NMR (125 MHz): 111.2 (d), 113.2 (d), 117.8 (t), 119.0, 120.1 (t), 121.8, 128.2, 130.2, 130.9, 132.3, 137.6, 148.0, 148.3 (t) ppm. –  $^{19}\text{F}$  NMR (282 MHz):  $-80.7, -114.8$  ppm. – IR: 1069, 1122, 1199, 1254, 1319, 1417, 2956, 3006, 3042  $\text{cm}^{-1}$ . – MS (ESI): 326.0, HRMS: 325.9560, calcd: 325.9598  $[\text{M}+\text{H}^+]$ .

**8-Methoxy-2-(perfluorophenyl)quinoline (17)**—According to GP1, to a stirred solution of 8-methoxyquinoline *N*-oxide (35 mg, 0.20 mmol), 3 Å molecular sieves (50 mg), and trimethyl(pentafluorophenyl)silane (57  $\mu\text{L}$ , 0.30 mmol, 1.5 equiv.) in tetrahydrofuran (1 mL) was added potassium *tert*-butoxide (23 mg, 0.20 mmol, 1 equiv.) in 3 portions over 30 min at  $-20\text{ }^\circ\text{C}$ . After 10 min the reaction was worked up and the crude product purified by column chromatography to yield quinoline **17** (11 mg, 17 %). –  $^1\text{H}$  NMR (500 MHz): 4.10



(3 H, s), 7.13 (1 H, dd,  $J = 1, 8$  Hz), 7.43 – 7.57 (3 H, m), 8.27 (1 H, d,  $J = 8.5$  Hz) ppm. –  $^{13}\text{C}$  NMR (125 MHz): 56.3, 108.6, 119.3, 123.3, 124.9, 127.4, 128.0, 128.4, 128.7, 135.7, 136.8, 140.3, 145.7, 155.6 ppm. –  $^{19}\text{F}$  NMR (282): –161.2 (m), –153.0 (t), –140.1 (m) ppm. – IR: 1110, 1176, 1213, 1315, 1380, 1446, 1505, 2842, 2937, 3046  $\text{cm}^{-1}$ . – MS (ESI): 325.9, HRMS: 326.0649, calcd: 326.0599 [ $\text{M}+\text{H}^+$ ].

**8-Methoxy-2-(perfluoroethyl)quinoline (18)**—According to GP1, to a stirred solution of 8-methoxyquinoline *N*-oxide (35 mg, 0.20 mmol), 3 Å molecular sieves (50 mg), and trimethyl(pentafluoroethyl)silane (53  $\mu\text{L}$ , 0.30 mmol, 1.5 equiv.) in tetrahydrofuran (1 mL) was added potassium *tert*-butoxide (67 mg, 0.60 mmol, 3 equiv.) in 3 portions over 30 min at –20 °C. After 10 min the reaction was worked up and the crude product was purified by column chromatography to yield quinoline **18** (49 mg, 86 %). –  $^1\text{H}$  NMR (500 MHz): 4.10 (3 H, s), 7.15 (1 H, d,  $J = 8$  Hz), 7.46 (1 H, d,  $J = 8.5$  Hz), 7.61 (1 H, t,  $J = 8$  Hz), 7.77 (1 H, d,  $J = 8.5$  Hz), 8.32 (1 H, d,  $J = 8.5$  Hz) ppm. –  $^{13}\text{C}$  NMR (125 MHz): 56.4, 109.2, 111.2 (d), 113.5 (d), 117.9 (t), 118.5, 119.2, 120.18 (t), 128.3, 129.1, 130.0, 137.7, 139.5, 146.0 (t), 156.0 ppm. –  $^{19}\text{F}$  NMR (282 MHz): –116.5 (t), –82.8 (quart.) ppm. – IR: 1213, 1314, 1445, 2899, 2985, 3025  $\text{cm}^{-1}$ . – MS (ESI): 277.9, HRMS: 278.054, calcd: 278.0599 [ $\text{M}+\text{H}^+$ ].

**1-(Perfluoroethyl)isoquinoline<sup>20</sup> (19)**—According to GP1, to a stirred solution of isoquinoline-*N*-oxide (30 mg, 0.20 mmol), 3 Å molecular sieves (50 mg), and trimethyl(pentafluoroethyl)silane (53  $\mu\text{L}$ , 0.30 mmol, 1.5 equiv.) in tetrahydrofuran (1 mL) was added potassium *tert*-butoxide (67 mg, 0.60 mmol, 3 equiv.) in 3 portions over 30 min at –20 °C. After 10 min the reaction was worked up and the crude product purified by column chromatography to yield isoquinoline **19** (27 mg, 55 %). –  $^1\text{H}$  NMR (500 MHz): 7.73 (1 H, dt,  $J = 1, 6.5$  Hz), 7.79 (1 H, dt,  $J = 1, 6.5$  Hz), 7.87 (1 H, d,  $J = 5.5$  Hz), 7.96 (1 H, d,  $J = 8$  Hz), 8.40 (1 H, d,  $J = 8.5$  Hz), 8.63 (1 H, d,  $J = 5.5$  Hz) ppm. –  $^{13}\text{C}$  NMR (125 MHz): 111.5 (d), 113.5 (d), 115.5 (m), 118.1 (t), 120.4 (t), 124.4, 124.8, 125.9, 127.7, 128.8, 130.7, 137.2, 140.8, 146.3 (m) ppm. –  $^{19}\text{F}$  NMR (282 MHz): –81.2, –107.7 ppm. – IR: 1071, 1122, 1174, 1260, 1319, 1474, 2920, 2963, 3028  $\text{cm}^{-1}$ .

**2-(Difluoromethyl)-8-methoxyquinoline (20)**—According to GP1, to a stirred solution of 7-chloro-4-(isopropylthio)quinoline *N*-oxide (53 mg, 0.30 mmol), 3 Å molecular sieves (50 mg), and trimethyl(difluoromethyl)silane (150  $\mu\text{L}$ , 0.45 mmol, 5 equiv.) in tetrahydrofuran (3 mL) was added potassium *tert*-butoxide (135 mg, 0.90 mmol, 4 equiv.) in 3 portions over 30 min at –20 °C. After 30 min the reaction was worked up and the crude product purified by column chromatography to yield quinoline **20** (51 mg, 81 %). –  $^1\text{H}$  NMR (500 MHz): 3.89 (3 H, s), 4.77 (1 H, br s), 5.43 (1 H, dd,  $J = 2.5, 10$  Hz), 5.69 – 5.95 (1 H, m), 6.63 – 6.76 (4 H, m) ppm. –  $^{13}\text{C}$  NMR (125 MHz): 55.6, 110, 111.2, 111.8, 111.9, 113.8, 113.9, 115.9, 117.5, 117.7, 119.9, 130.4, 131.9, 145.1 ppm. –  $^{19}\text{F}$  NMR (282 MHz): –132.8 (d) ppm. – IR: 1110, 1213, 1345, 1415, 1556, 2898, 3026  $\text{cm}^{-1}$ . – MS (ESI): 210.0, HRMS: 210.0721, calcd: 210.0725 [ $\text{M}+\text{H}^+$ ].

**7-Chloro-2-(difluoromethyl)-4-(isopropylthio)quinoline (21)**—According to GP1, to a stirred solution of 7-chloro-4-(isopropylthio)quinoline *N*-oxide (76 mg, 0.30 mmol), 3 Å molecular sieves (50 mg), and trimethyl(difluoromethyl)silane (150  $\mu\text{L}$ , 1.50 mmol, 5

equiv.) in tetrahydrofuran (3 mL) was added potassium *tert*-butoxide (134 mg, 1.20 mmol, 4 equiv.) in 3 portions over 30 min at  $-20\text{ }^{\circ}\text{C}$ . After 30 min the reaction was worked up and the crude product purified by column chromatography to yield quinoline **21** (30 mg, 34 %). –  $^1\text{H}$  NMR (500 MHz): 1.36 (6 H, d,  $J = 6.5$  Hz), 3.31 (1 H, sept.,  $J = 6.5$  Hz), 4.37 (1 H, br s), 5.45 (1 H, d,  $J = 2$  Hz), 5.83 (1 H, m), 6.60 (1 H, d,  $J = 2$  Hz), 6.71 (1 H, dd,  $J = 2, 8$  Hz), 7.43 (1 H, d,  $J = 8$  Hz) ppm. –  $^{13}\text{C}$  NMR (125 MHz): 22.6, 36.4, 110.8, 111.6, 113.1, 113.6, 115.6, 116.7, 118.9, 126.9, 136.0, 137.5, 141.8 ppm. –  $^{19}\text{F}$  NMR (282 MHz):  $-132.2$  (dd) ppm. – IR: 1093, 1263, 1368, 1414, 2905, 2964, 3013  $\text{cm}^{-1}$ . – MS (ESI): 287.0, HRMS: 287.0167, calcd: 287.0347  $[\text{M}+\text{H}^+]$ .

**4-(*tert*-Butylthio)-7-chloro-2-(difluoromethyl)quinoline (22)**—According to GP1, to a stirred solution of 4-(*tert*-butylthio)-7-chloroquinoline *N*-oxide (80 mg, 0.3 mmol), 3Å molecular sieves (50 mg), and trimethyl(difluoromethyl)silane (150  $\mu\text{L}$ , 1.50 mmol, 5 equiv.) in tetrahydrofuran (3 mL) was added potassium *tert*-butoxide (134 mg, 1.20 mmol, 4 equiv.) in 3 portions over 30 min at  $-20\text{ }^{\circ}\text{C}$ . After 30 min the reaction was worked up and the crude product purified by column chromatography to yield quinoline **22** (47 mg, 52 %). –  $^1\text{H}$  NMR (500 MHz): 1.35 (9 H, s), 4.34 (1 H, br s), 5.72–5.97 (2 H, m), 6.58 (1 H, d,  $J = 2$  Hz), 6.72 (1 H, dd,  $J = 2, 8.5$  Hz), 7.70 (1 H, d,  $J = 8$  Hz) ppm. –  $^{13}\text{C}$  NMR (75 MHz): 31.3, 112.9, 113.4, 116.7, 118.6, 119.9, 122.2, 129.2, 131.0, 135.9, 141.8 ppm. –  $^{19}\text{F}$  NMR (282 MHz):  $-132.1$  (d) ppm. – IR: 1093, 1213, 1368, 1475, 2995, 3025  $\text{cm}^{-1}$ . – MS (ESI): 302.1, HRMS: 302.0599, calcd: 302.0576  $[\text{M}+\text{H}^+]$ .

**8-Methoxy-2-(2,3,5,6-tetrafluoro-4-(phenylthio)phenyl)-quinoline (23)**—According to GP1, to a stirred solution of 8-methoxyquinoline *N*-oxide (35 mg, 0.20 mmol), 3Å molecular sieves (50 mg), sodium thiophenolate (158 mg, 1.20 mmol, 6 equiv.), and trimethyl(pentafluorophenyl)silane (57  $\mu\text{L}$ , 0.30 mmol, 1.5 equiv.) in tetrahydrofuran (2 mL) was added potassium *tert*-butoxide (67 mg, 0.60 mmol, 3 equiv.) in 3 portions over 30 min at  $-20\text{ }^{\circ}\text{C}$ . After 10 min the reaction was worked up and the crude product purified by column chromatography to yield quinoline **23** (72 mg, 86 %). –  $^1\text{H}$  NMR (500 MHz): 4.10 (3 H, s), 7.14 (1 H, d,  $J = 7.5$  Hz), 7.31 – 7.37 (5 H, m), 7.42 (1 H, d,  $J = 7.5$  Hz), 7.45 (1 H, d,  $J = 8$  Hz), 7.55 – 7.61 (1 H, m), 8.28 (1 H, d,  $J = 8.5$  Hz) ppm. –  $^{13}\text{C}$  NMR (125 MHz): 56.3, 108.3 (m), 119.4, 123.3, 124.7, 127.2, 127.5, 127.8, 129.2, 129.4, 129.6, 130.4, 135.7, 135.7, 139.9, 146.3, 155.6 (m) ppm. –  $^{19}\text{F}$  NMR (282 MHz):  $-133.0$  (dd),  $-142.3$  (dd) ppm. – IR: 1111, 1260, 1323, 1379, 1479, 1561, 2874, 2942, 3024  $\text{cm}^{-1}$ . – MS (ESI): 415.8, HRMS: 416.0784, calcd: 416.0727  $[\text{M}+\text{H}^+]$ .

**2-(4-(*tert*-Butoxy)-2,3,5,6-tetrafluorophenyl)-8-methoxy-quinoline (24)**—According to GP1, to a stirred solution of 8-methoxyquinoline *N*-oxide (35 mg, 0.20 mmol), 3Å molecular sieves (50 mg), and trimethyl(pentafluorophenyl)silane (57  $\mu\text{L}$ , 0.3 mmol, 1.50 equiv.) in tetrahydrofuran (2 mL) was added potassium *tert*-butoxide (67 mg, 0.60 mmol, 3 equiv.) in 3 portions over 30 min at  $-20\text{ }^{\circ}\text{C}$ . After 10 min the reaction was worked up and the crude product purified by column chromatography to yield quinoline **24** (63 mg, 83 %). –  $^1\text{H}$  NMR (500 MHz): 1.46 (9 H, s), 4.08 (3 H, s), 7.11 (1 H, d,  $J = 7.5$  Hz), 7.45 (1 H, d,  $J = 8.5$  Hz), 7.54 (1 H, t,  $J = 7.5$  Hz), 7.58 (1 H, d,  $J = 7.5$  Hz), 8.25 (1 H, d,  $J = 8.5$  Hz) ppm. –  $^{13}\text{C}$  NMR (125 MHz): 56.3, 108.6, 119.4, 123.4, 128.0, 128.3, 128.7, 136.8,

140.3, 145.7, 155.6 ppm. –  $^{19}\text{F}$  NMR (282 MHz):  $-140.1$  (m),  $-161.3$  (m) ppm. – IR: 1110, 1211, 1345, 1445, 2899,  $3026\text{ cm}^{-1}$ . – MS (ESI):  $401.9$  [ $\text{M}+\text{Na}^+$ ], HRMS:  $380.0725$ , calcd:  $380.1268$  [ $\text{M}+\text{H}^+$ ].

**2-(4-(*tert*-Butoxy)-2,3,5,6-tetrafluorophenyl)-5-chloro-8-methoxyquinoline (25)**

—According to GP1, to a stirred solution of 5-chloro-8-methoxyquinoline *N*-oxide (42 mg, 0.20 mmol), 3 Å molecular sieves (50 mg), and trimethyl(pentafluorophenyl)silane (57  $\mu\text{L}$ , 0.30 mmol, 1.5 equiv.) in tetrahydrofuran (2 mL) was added potassium *tert*-butoxide (67 mg, 0.60 mmol, 3 equiv.) in 3 portions over 30 min at  $-20\text{ }^\circ\text{C}$ . After 10 min the reaction was worked up and the crude product purified by column chromatography to yield quinoline **25** (69 mg, 83 %). –  $^1\text{H}$  NMR (300 MHz): 1.45 (9 H, s), 4.08 (3 H, s), 7.03 (1 H, d,  $J = 9.5$  Hz), 7.61 (1 H, d,  $J = 9.5$  Hz), 7.71 (1 H, dt,  $J = 1.5, 9.5$  Hz), 8.66 (1 H, d,  $J = 9.5$  Hz) ppm. –  $^{13}\text{C}$  NMR (125 MHz): ppm. –  $^{19}\text{F}$  NMR (282 MHz):  $-140.5$  (m),  $-151.5$  (m) ppm. – IR: 1092, 1104, 1159, 1246, 1310, 1372, 1423, 1488, 2963, 2995,  $3042\text{ cm}^{-1}$ . – MS (ESI):  $414.1$ , HRMS:  $414.0907$ , calcd:  $414.0878$  [ $\text{M}+\text{H}^+$ ].

**5-Bromo-2-(4-(ethylthio)-2,3,5,6-tetrafluorophenyl)quinoline (26)**

—According to GP1, to a stirred solution of 5-bromoquinoline *N*-oxide (45 mg, 0.20 mmol), 3 Å molecular sieves (50 mg), sodium ethanethiolate (101 mg, 1.20 mmol, 6 equiv.), and trimethyl(difluoromethyl)silane (60  $\mu\text{L}$ , 0.3 mmol, 1.50 equiv.) in tetrahydrofuran (2 mL) was added potassium *tert*-butoxide (90 mg, 0.8 mmol, 4 equiv.) in 3 portions over 30 min at  $-20\text{ }^\circ\text{C}$ . After 10 min the reaction was worked up and the crude product purified by column chromatography to yield quinoline **26** (37 mg, 45 %). –  $^1\text{H}$  NMR (300 MHz): 1.33 (3 H, t,  $J = 4.5$  Hz), 3.05 (1 H, quart.,  $J = 4.5$  Hz), 7.61–7.71 (2 H, m), 7.91 (1 H, dd,  $J = 1, 8.5$  Hz), 8.15 (1 H, dd,  $J = 1, 9.5$  Hz), 8.68 (1 H, d,  $J = 9.5$  Hz) ppm. –  $^{13}\text{C}$  NMR (75 MHz): 15.1, 28.9, 121.9, 123.9, 127.0 (d), 129.7, 130.5, 131.4, 138.2 (d), 148.8 (m) ppm. –  $^{19}\text{F}$  NMR (282 MHz):  $-133.7$  (dd),  $-143.2$  (dd) ppm. – IR: 1110, 1213, 1333, 1415, 1554, 2989,  $3014\text{ cm}^{-1}$ . – MS (ESI):  $416.0$ , HRMS:  $415.9701$ , calcd:  $415.9726$  [ $\text{M}+\text{H}^+$ ].

**5,7-Dichloro-8-methoxyquinoline 1-oxide (27)**

—To a stirred solution of 5,7-dichloro-8-methoxyquinoline (500 mg, 2.19 mmol) in dichloromethane (5 mL) was added *meta*-chloroperoxybenzoic acid (980 mg, 2.85 mmol, 1.3 equiv., 50 % solution in  $\text{H}_2\text{O}$ ) at  $0\text{ }^\circ\text{C}$ . After 12 h the reaction was diluted with a saturated aqueous solution of sodium thiosulfate/sodium carbonate (30 mL, 1:1), and the aqueous layer extracted with dichloromethane ( $4 \times 10\text{ mL}$ ). The combined organic layers were dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by column chromatography to yield *N*-oxide **27** (341 mg, 64 %). – m.p.:  $138\text{--}140\text{ }^\circ\text{C}$ . –  $^1\text{H}$  NMR (500 MHz): 4.09 (3 H, s), 7.32–7.36 (1 H, m), 7.75 (1 H, s), 8.02 (1 H, d,  $J = 8.5$  Hz), 8.48 (1 H, d,  $J = 8.5$  Hz) ppm. –  $^{13}\text{C}$  NMR (125 MHz): 63.1, 121.5, 122.1, 127.3, 129.8, 130.0, 130.1, 138.9, 139.1, 148.4 ppm. – IR: 1098, 1225, 1392, 1558, 2880, 2938,  $3012\text{ cm}^{-1}$ . – MS (ESI):  $244.0$ , HRMS:  $243.9987$ , calcd:  $243.9927$  [ $\text{M}+\text{H}^+$ ].

**8-(*tert*-Butoxy)-5,7-dichloro-2-(trifluoromethyl)quinoline (28)**

—According to GP1, to a stirred solution of **27** (49 mg, 0.20 mmol), 3 Å molecular sieves (50 mg), and trimethyl(trifluoromethyl)silane (45  $\mu\text{L}$ , 0.30 mmol, 1.5 equiv.) in tetrahydrofuran (1 mL) at

– 20 °C was added potassium *tert*-butoxide (66 mg, 0.60 mmol, 3 equiv.) in 3 portions over 30 min. After 3 h the reaction was worked up and the crude product purified by column chromatography to yield quinoline **28** (37 mg, 54 %). – <sup>1</sup>H NMR (500 MHz): 1.57 (9 H, s), 7.80 (1 H, s), 7.82 (1 H, d, *J* = 8.5 Hz), 8.70 (1 H, d, *J* = 8.5 Hz) ppm. – <sup>13</sup>C NMR (125 MHz): 29.7, 86.3, 102.5, 117.5, 122.5, 126.7, 130.1, 130.7, 135.7, 145.0, 148.2 (d, *J* = 2 Hz), 150.1 ppm. – <sup>19</sup>F NMR (282 MHz): –67.4 ppm. – IR: 1102, 1189, 1262, 1339, 1443, 2953, 2988, 3028 cm<sup>-1</sup>. – MS (ESI): 376.0, HRMS: 375.9874, calcd: 375.9880 [M+K<sup>+</sup>].

**8-(*tert*-Butoxy)-5,7-dichloro-2-(perfluoroethyl)quinoline (29)**—According to GP1, to a stirred solution of **27** (49 mg, 0.20 mmol), 3 Å molecular sieves (50 mg), and trimethyl(pentafluoroethyl)silane (53 μL, 0.30 mmol, 1.5 equiv.) in tetrahydrofuran (1 mL) was added potassium *tert*-butoxide (67 mg, 0.6 mmol, 3 equiv.) in 3 portions over 30 min at –20 °C. After 3 h the reaction was worked up and the crude product was purified by column chromatography to yield quinoline **29** (34 mg, 44 %). – <sup>1</sup>H NMR (500 MHz): 1.57 (9 H, s), 7.80 (1 H, s), 7.82 (1 H, d, *J* = 8.5 Hz), 8.70 (1 H, d, *J* = 8.5 Hz) ppm. – <sup>13</sup>C NMR (125 MHz): 29.6, 86.4, 110.0, 111.3 (m), 113.7, 125.5, 126.6, 130.2, 130.8, 135.5, 145.3, 147.9, 150.1 ppm. – <sup>19</sup>F NMR (282 MHz): –82.9, –116.9 ppm. – IR: 1011, 1158, 1262, 1300, 1393, 1440, 1585, 2934, 2980, 3035 cm<sup>-1</sup>. – MS (ESI): 388.0, HRMS: 388.0566, calcd: 388.0289 [M+H<sup>+</sup>].

**5,7-Dichloro-2-(trifluoromethyl)quinolin-8-ol (31)**—To a solution of **28** (12 mg, 0.04 mmol) in dichloromethane (4 mL) at 23 °C was added trifluoromethanesulfonic acid (36 mg, 0.24 mmol, 6 equiv.). After 12 h the reaction was diluted with a saturated aqueous solution of sodium bicarbonate (10 mL) and the aqueous layer extracted with dichloromethane (3 × 10 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure to yield chlorquinaldol analogue **31** (10 mg, 88 %). – <sup>1</sup>H NMR (500 MHz): 7.76 (1 H, s), 7.92 (1 H, d, *J* = 9 Hz), 8.74 (1 H, d, *J* = 9 Hz) ppm. – <sup>13</sup>C NMR (125 MHz): 104.5, 110.0, 117.2, 118.3, 121.0, 125.9, 130.6, 136.2, 137.6, 148.0 (m) ppm. – <sup>19</sup>F NMR (282 MHz): –67.4 ppm. – IR: 908, 1104, 1187, 1316, 1351, 1465, 2991, 3031, 3359 cm<sup>-1</sup>. – MS (ESI): 282.0, HRMS: 281.9666, calcd: 281.9695 [M+H<sup>+</sup>].

**5,7-Dichloro-2-(perfluoroethyl)quinolin-8-ol (32)**—To a solution of **29** (15 mg, 0.04 mmol) in dichloromethane (4 mL) at 23 °C was added trifluoromethanesulfonic acid (36 mg, 0.24 mmol, 6 equiv.). After 12 h the reaction was diluted with a saturated aqueous solution of sodium bicarbonate (10 mL) and the aqueous layer extracted with dichloromethane (3 × 10 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure to yield chlorquinaldol analogue **32** (12 mg, 90 %). – <sup>1</sup>H NMR (500 MHz): 7.76 (1 H, s), 7.92 (1 H, d, *J* = 9 Hz), 8.74 (1 H, d, *J* = 9 Hz) ppm. – <sup>13</sup>C NMR (125 MHz): 104.5, 109.89, 117.2, 118.4, 121.0, 125.8, 130.6, 136.1, 137.5, 147.8 (m) ppm. – <sup>19</sup>F NMR (282 MHz): –82.7, –116.6 ppm. – IR: 960, 1121, 1163, 1331, 1460, 2925, 2963, 3033, 3442 cm<sup>-1</sup>. – MS (ESI): 331.9, HRMS: 331.9659, calcd: 331.9663 [M+H<sup>+</sup>].

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments





Financial support by the Welch Foundation (AX-1788), the National Institute of General Medical Sciences (SC3GM105579), the Max and Minnie Tomerlin Voelcker Fund, NIH MBRS-RISE (GM060655), and the University of Texas at San Antonio is gratefully acknowledged. Mass spectroscopic analysis was supported by a grant from the National Institute on Minority Health and Health Disparities (G12MD007591).

## References


- (a) Müller K, Faeh C, Diederich F. *Science*. 2007; 317:1881–1886. [PubMed: 17901324] (b) Purser S, Moore PP, Swallow S, Gouverneur V. *Chem Soc Rev*. 2008; 37:320–330. [PubMed: 18197348] (c) O'Hagan D. *Chem Soc Rev*. 2008; 37:308–319. [PubMed: 18197347] (d) Wang J, Sánchez-Roselló, Luis Aceña J, del Pozo C, Sorochinsky AE, Fustero S, Soloshonok VA, Liu H. *Chem Rev*. 2014; 114:2432–2506. [PubMed: 24299176]
- (a) Nakajima, T.; Groult, H., editors. *Fluorinated Materials for Energy Conversion*. Elsevier; 2005. (b) Pagliaro M, Ciriminna R. *J Mater Chem*. 2005; 15:4981–4991.
- (a) Merino E, Nevado C. *Chem Soc Rev*. 2014; 43:1039–1039/c4cs00025k(b) Liu T, Shen Q. *Eur J Org Chem*. 2012; 6679–6687. (c) Tomashenko OA, Grushin VV. *Chem Rev*. 2011; 111:4475–4521. [PubMed: 21456523] (d) Wu XF, Neumann H, Beller M. *Chem Asian J*. 2012; 7:1744–1754. [PubMed: 22715145] (e) Roy S, Gregg BT, Gribble GW, Le VD, Roy S. *Tetrahedron*. 2011; 67:2161–2195.
- (a) Nagib DA, MacMillan DW. *Nature*. 2011; 480:224–228. [PubMed: 22158245] (b) Ji Y, Brueckl T, Baxter RD, Fujiwara Y, Seiple IB, Su S, Blackmond DG, Baran PS. *Proc Natl Acad Sci USA*. 2011; 108:14411–14415. [PubMed: 21844378] (c) Chu L, Qing FL. *J Am Chem Soc*. 2012; 134:1298–304. [PubMed: 22145831]
- (a) Caron S, Do NM, Sieser JE. *Tetrahedron Lett*. 2000; 41:2299. (b) Balicki R, Golinski J. *Synth Commun*. 2000; 30:1529. (c) Rosenau T, Potthast A, Kosma P. *Synlett*. 1999:1972. (d) Larionov OV, Stephens D, Mfuh AM, Arman HD, Naumova AS, Chavez G, Skenderi B. *Org Biomol Chem*. 2014; 12:3026. [PubMed: 24643619] (e) Coperet C, Adolfsson H, Khuong TAW, Yudin AK, Sharpless KB. *J Org Chem*. 1998; 63:1740.
- (a) Campeau LC, Rousseaux S, Fagnou K. *J Am Chem Soc*. 2005; 127:18020. [PubMed: 16366550] (b) Kanyiva KS, Nakao Y, Hiyama T. *Angew Chem Int Ed*. 2007; 46:8872. (c) Cho SH, Hwang SJ, Chang S. *J Am Chem Soc*. 2008; 130:9254–9256. [PubMed: 18582040] (d) Wu J, Cui X, Chen L, Jiang G, Wu Y. *J Am Chem Soc*. 2009; 131:13888–13889. [PubMed: 19746974] (e) Xiao B, Liu ZJ, Liu L, Fu Y. *J Am Chem Soc*. 2013; 135:616–619. [PubMed: 23282325] (f) Larionov OV, Stephens D, Mfuh A, Chavez G. *Org Lett*. 2014; 16:864–867. [PubMed: 24410049] (g) Zhu C, Yi M, Wei D, Chen X, Wu Y, Cui X. *Org Lett*. 2014; 16:1840–1843. [PubMed: 24628081]
- (a) Wengryniuk SE, Weickgenannt A, Reiher C, Strotman NA, Chen K, Eastgate MD, Baran PS. *Org Lett*. 2013; 15:792. [PubMed: 23350852] (b) Paudler WW, Jovanovic MV. *J Org Chem*. 1983; 48:1064.
- (a) Londregan AT, Jennings S, Wei L. *Org Lett*. 2011; 13:1840. [PubMed: 21375291] (b) Keith JM. *J Org Chem*. 2010; 75:2722. [PubMed: 20297806] (c) Londregan AT, Jennings S, Wei LQ. *Org Lett*. 2010; 12:5254. [PubMed: 20958085] (d) Storz T, Bartberger MD, Sukits S, Wilde C, Soukup T. *Synthesis*. 2008:201. (e) Yin J, Xiang B, Huffman MA, Raab CE, Davies IW. *J Org Chem*. 2007; 72:4554. [PubMed: 17500567]
- (a) Liu X, Xu C, Wang M, Liu Q. *Chem Rev*. 2014; 114:1021–1021/cr400473a(b) Prakash GKS, Mandal M. *J Fluorine Chem*. 2001; 112:123–131. (c) Ma JA, Cahard D. *J Fluorine Chem*. 2007; 128:975–996. (d) Prakash GKS, Krishnamurti R, Olah GA. *J Am Chem Soc*. 1989; 111:393. (e) Ruppert I, Schlich K, Volbach W. *Tetrahedron Lett*. 1984; 25:2195.
- (a) Prakash GKS, Krishnamoorthy S, Ganesh SK, Kulkarni A, Haiges R, Olah GA. *Org Lett*. 2014; 16:54–57. [PubMed: 24295125] (b) Prakash GKS, Yudin AK. *Chem Rev*. 1997; 97:757–786. [PubMed: 11848888]
- (a) World Pat, WO. 2007133637. 2007. (b) World Pat, WO. 2008059370. 2008. (c) World Pat, WO. 2009064449. 2009.
- Nishida T, Ida H, Kuninobu Y, Kanai M. *Nature Comm*. 2014; 5:1038/ncomms4387

13. Loska R, Majcher M, Makosza M. *J Org Chem.* 2007; 72:5574–5580. [PubMed: 17585813]
14. (a) Pino P, Piccolo O, Straub B, Consiglio G, Dich CT. *Helv Chim Acta.* 1982; 65:2102–2109. (b) Wendeborn S, Winkler T, Foisy I. *Tetrahedron Lett.* 2000; 41:6387–6391. (c) Matsumoto K, Kannami M, Inokuchi D, Kurata H, Kawase T, Oda M. *Org Lett.* 2007; 9:2903–2906. [PubMed: 17602492]
15. (a) Shabalin AY, Adonin NY, Bardin VV, Prikhod'ko SA, Timofeeva MN, Bykova MV, Parmon VN. *J Fluorine Chem.* 2013; 149:82–87. (b) Yu D, Lu L, Shen Q. *Org Lett.* 2013; 15:940–943. [PubMed: 23391131] (c) Liu C, Cao L, Yin X, Xu H, Zhang B. *J Fluorine Chem.* 2013; 156:51–60. (d) Filler R, Ayyangar NR, Gustowski W, Kang HH. *J Org Chem.* 1969; 34:534–538.
16. Terenin VI, Gerasimenko VA, Nikishova NG, Kurts AL, Afanas'eva TA, Bundel YG. *Zh Org Khim.* 1990; 26:2191–2198.
17. Tobisu M, Yasutome A, Yamakawa K, Shimasaki T, Chatani N. *Tetrahedron.* 2012; 68:5157–5161.
18. (a) Kolomeitsev A, Rusanov E, Bissky G, Lork E, Röschenthalet GV, Kirsch P. *Chem Commun.* 1999:1017–1018. (b) Suzuki Y, Bakar A, Muramatsu MDK, Sato M. *Tetrahedron.* 2006; 62:4227–4231.






**Fig. 1.**  
Representative bioactive *N*-heterocycles bearing trifluoro- and difluoromethyl groups.


**Scheme 1.**

Dual substitution reaction of 8-methoxyquinoline *N*-oxides with perfluoroalkylsilanes.

**Scheme 2.**

Kinetic isotope effect in the trifluoromethylation reaction of isoquinoline *N*-oxide.


Table 1

Optimization of the reaction conditions.<sup>a</sup>


Entry	Base/fluoride (equiv)	Solvent	T (°C)	2 : 3 : quinolineRatio <sup>b</sup>	Yield <sup>b</sup> of 3, %
1	TBAF (0.2)	THF	23	7 : 1 : 1	11
2	TBAF (0.2)	PhCH <sub>3</sub> /THF (1:1)	23	1.7 : 1.5 : 1	34
3	TBAF (0.2)	PhCH <sub>3</sub> /THF (1:1)	65	10 : 1 : 1.5	8
4	TASF (1.1)	PhCH <sub>3</sub> /THF (1:1)	23	2 : 2.5 : 1	44
5	CsF (1.1)	PhCH <sub>3</sub> /THF (1:1)	23	1.6 : 1.7 : 1	34
6 <sup>c</sup>	TASF (1.1)	PhCH <sub>3</sub> /THF (1:1)	23	1.3 : 2.5 : 1	50
7 <sup>d</sup>	TASF (1.1)	THF	23	1.5 : 2.1 : 1	44
8	KO <sup>t</sup> -Bu (1.1)	THF	23	1 : 6.8 : 17.3	26
9	KO <sup>i</sup> -Bu (3)	THF	23	1 : 3.2 : 5.8	32
10 <sup>e</sup>	KO <sup>t</sup> -Bu (3)	THF	-20	1 : 29 : 3.2	87


<sup>a</sup>Reaction conditions: **2** (0.35 or 1 mmol), **1** (2.5 equiv), in the solvent (c=0.7 M) under Ar for 2 h.<sup>b</sup>Determined by <sup>1</sup>H NMR.<sup>c</sup>(CuOTf)<sub>2</sub>·PhIh (5 mol %) was added.<sup>d</sup>MgCl<sub>2</sub> (2 equiv) was added.<sup>e</sup>c=0.2 M.

Table 2

Scope of the trifluoromethylation reaction of heterocyclic *N*-oxides.<sup>a</sup>

<sup>a</sup> Reaction conditions: heterocyclic *N*-oxide (0.2 or 0.5 mmol), **1** (1.5 equiv),  $\text{KO}t\text{-Bu}$  (3 equiv), 3Å MS, THF ( $c=0.2$  M), at  $-20$  °C under Ar for 50 min.

Table 3

Reaction of perfluoroalkyl/phenylsilanes with heterocyclic *N*-oxides.<sup>a</sup>

<sup>a</sup>Reaction conditions: heterocyclic *N*-oxide (0.2–0.5 mmol),  $C_nF_mSiMe_3$  (1.5 equiv),  $KOt-Bu$  (3 equiv), 3Å MS, THF ( $c=0.2$  M), at  $-20$  °C under Ar for 50 min.


<sup>b</sup>1 equiv  $KOt-Bu$  was used.

<sup>c</sup> $CHF_2SiMe_3$  (5 equiv),  $KOt-Bu$  (4 equiv), THF ( $c=0.1$  M) was used.



Table 4

Dual substitution reaction of heterocyclic *N*-oxides with (pentafluorophenyl)trimethylsilane and additional nucleophiles.<sup>a</sup>



<sup>a</sup>Reaction conditions: heterocyclic *N*-oxide (0.2 mmol),  $C_6F_5SiMe_3$  (1.5 equiv),  $KOt-Bu$  (3 equiv), 3Å MS, THF ( $c=0.1$  M), at  $-20$  °C under Ar for 50 min.

<sup>b</sup>NaSPh (6 equiv) was added.

<sup>c</sup>NaSC<sub>2</sub>H<sub>5</sub> (6 equiv) was added.